Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JEFFREY N MYERS and CURTIS R PICKERING.
JEFFREY N MYERS
Connection Strength
5.042
CURTIS R PICKERING
  1. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin Cancer Res. 2014 Jul 15; 20(14):3842-8.
    View in: PubMed
    Score: 0.504
  2. Bcl-2 inhibition or FBXW7 mutation sensitizes solid tumor cells to HDAC inhibition in vitro but could prove difficult to validate in patients. Cancer Discov. 2013 Mar; 3(3):258-9.
    View in: PubMed
    Score: 0.462
  3. Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234. Adv Radiat Oncol. 2022 Nov-Dec; 7(6):100989.
    View in: PubMed
    Score: 0.219
  4. Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight. 2020 12 03; 5(23).
    View in: PubMed
    Score: 0.198
  5. Loss of p53 drives neuron reprogramming in head and neck cancer. Nature. 2020 02; 578(7795):449-454.
    View in: PubMed
    Score: 0.187
  6. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019 Jan 10; 4(1).
    View in: PubMed
    Score: 0.173
  7. High-Risk TP53 Mutations Are Associated with Extranodal Extension in Oral Cavity Squamous Cell Carcinoma. Clin Cancer Res. 2018 04 01; 24(7):1727-1733.
    View in: PubMed
    Score: 0.162
  8. CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Res. 2018 02 01; 78(3):781-797.
    View in: PubMed
    Score: 0.161
  9. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma. Head Neck. 2017 06; 39(6):1131-1137.
    View in: PubMed
    Score: 0.152
  10. New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prev Res (Phila). 2015 Nov; 8(11):1027-35.
    View in: PubMed
    Score: 0.138
  11. Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
    View in: PubMed
    Score: 0.132
  12. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014 Dec 15; 20(24):6582-92.
    View in: PubMed
    Score: 0.129
  13. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head Neck. 2014 Nov; 36(11):1547-54.
    View in: PubMed
    Score: 0.124
  14. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013 Jul; 3(7):770-81.
    View in: PubMed
    Score: 0.117
  15. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res. 2011 Nov 01; 17(21):6658-70.
    View in: PubMed
    Score: 0.104
  16. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res. 2011 Dec 01; 17(23):7248-64.
    View in: PubMed
    Score: 0.104
  17. Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012 Feb 01; 118(3):711-21.
    View in: PubMed
    Score: 0.103
  18. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer. 2011 Jul 01; 117(13):2926-38.
    View in: PubMed
    Score: 0.100
  19. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
    View in: PubMed
    Score: 0.061
  20. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun. 2024 Jan 02; 15(1):180.
    View in: PubMed
    Score: 0.061
  21. A Deep Learning Onion Peeling Approach to Measure Oral Epithelium Layer Number. Cancers (Basel). 2023 Jul 31; 15(15).
    View in: PubMed
    Score: 0.059
  22. Deep learning-based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia. Cancer Med. 2023 03; 12(6):7508-7518.
    View in: PubMed
    Score: 0.057
  23. Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 12 08; 114(12):1619-1627.
    View in: PubMed
    Score: 0.057
  24. Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma. Commun Biol. 2022 07 28; 5(1):757.
    View in: PubMed
    Score: 0.055
  25. High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022; 10:936168.
    View in: PubMed
    Score: 0.055
  26. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia. 2022 09; 31:100813.
    View in: PubMed
    Score: 0.055
  27. Induction chemotherapy with or without erlotinib in patients with head and neck squamous cell carcinoma amenable for surgical resection. Clin Cancer Res. 2022 Apr 20.
    View in: PubMed
    Score: 0.054
  28. A general calculus of fitness landscapes finds genes under selection in cancers. Genome Res. 2022 05; 32(5):916-929.
    View in: PubMed
    Score: 0.054
  29. Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
    View in: PubMed
    Score: 0.053
  30. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor. J Cell Physiol. 2021 11; 236(11):7698-7710.
    View in: PubMed
    Score: 0.051
  31. Mu-opioid receptor activation promotes in vitro and in vivo tumor growth in head and neck squamous cell carcinoma. Life Sci. 2021 Aug 01; 278:119541.
    View in: PubMed
    Score: 0.051
  32. The mutational landscape of early- and typical-onset oral tongue squamous cell carcinoma. Cancer. 2021 02 15; 127(4):544-553.
    View in: PubMed
    Score: 0.049
  33. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma. Cancer. 2020 10 15; 126(20):4498-4510.
    View in: PubMed
    Score: 0.048
  34. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. J Natl Cancer Inst. 2020 03 01; 112(3):266-277.
    View in: PubMed
    Score: 0.047
  35. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.
    View in: PubMed
    Score: 0.047
  36. Identification of markers predictive for response to induction chemotherapy in patients with sinonasal undifferentiated carcinoma. Oral Oncol. 2019 10; 97:56-61.
    View in: PubMed
    Score: 0.045
  37. Identification of novel diagnostic markers for sinonasal undifferentiated carcinoma. Head Neck. 2019 08; 41(8):2688-2695.
    View in: PubMed
    Score: 0.044
  38. Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma. BMC Cancer. 2018 Jul 24; 18(1):758.
    View in: PubMed
    Score: 0.042
  39. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Lett. 2018 09 01; 431:64-72.
    View in: PubMed
    Score: 0.042
  40. Risk Stratification of Oral Potentially Malignant Disorders in Fanconi Anemia Patients Using Autofluorescence Imaging and Cytology-On-A Chip Assay. Transl Oncol. 2018 Apr; 11(2):477-486.
    View in: PubMed
    Score: 0.041
  41. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma. Cancer. 2018 Jan 01; 124(1):84-94.
    View in: PubMed
    Score: 0.040
  42. Genomic characterization of human papillomavirus-positive and -negative human squamous cell cancer cell lines. Oncotarget. 2017 Oct 17; 8(49):86369-86383.
    View in: PubMed
    Score: 0.040
  43. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat Commun. 2017 09 06; 8(1):465.
    View in: PubMed
    Score: 0.040
  44. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res. 2017 Nov 01; 23(21):6541-6554.
    View in: PubMed
    Score: 0.039
  45. Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. 2017 Jun 01; 23(11):2713-2722.
    View in: PubMed
    Score: 0.039
  46. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017 04 28; 392:71-82.
    View in: PubMed
    Score: 0.038
  47. Cross-species identification of genomic drivers of squamous cell carcinoma development across preneoplastic intermediates. Nat Commun. 2016 08 30; 7:12601.
    View in: PubMed
    Score: 0.037
  48. Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50.
    View in: PubMed
    Score: 0.036
  49. Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma. Head Neck. 2016 04; 38 Suppl 1:E1926-34.
    View in: PubMed
    Score: 0.035
  50. Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence. Head Neck. 2016 04; 38 Suppl 1:E934-40.
    View in: PubMed
    Score: 0.034
  51. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24; 7(293):293ra104.
    View in: PubMed
    Score: 0.034
  52. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
    View in: PubMed
    Score: 0.033
  53. Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer. Epigenetics. 2014 Jul; 9(7):1031-46.
    View in: PubMed
    Score: 0.031
  54. Coordinated targeting of the EGFR signaling axis by microRNA-27a*. Oncotarget. 2013 Sep; 4(9):1388-98.
    View in: PubMed
    Score: 0.030
  55. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013 Sep; 12(9):1860-73.
    View in: PubMed
    Score: 0.030
  56. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013 Aug 15; 119(16):3034-42.
    View in: PubMed
    Score: 0.029
  57. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck. 2013 Mar; 35(3):454-63.
    View in: PubMed
    Score: 0.028
  58. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011 Aug 26; 333(6046):1154-7.
    View in: PubMed
    Score: 0.026
  59. Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol. 2011 Feb; 178(2):548-71.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.